Abstract

Breast cancer (BC) cells (BCCs) can retain cellular quiescence for decades, a phenomenon referred to as dormancy. BCCs show preference for the bone marrow (BM) where they can remain dormant for decades. Targeting BCCs within the BM is a challenge since the dormant BCCs reside within BM stroma, also residence for hematopoietic stem cells (HSCs). Dormant BCCs could behave as cancer stem cells (CSCs). The CSCs and HSCs are similar by function and also, by commonly expressed genes. The method by which dormant BCCs transition into clinically metastatic cells remains unclear. This study tested the hypothesis that macrophages (MΦs) within BM stroma, facilitates dormancy or reverse this state into metastatic cells. MΦs exhibiting an M2 phenotype constitute ~10% of cultured BM stroma. The M2 MΦs form gap junctional intercellular communication (GJIC) with CSCs, resulting in cycling quiescence, reduced proliferation and carboplatin resistance. In contrast, MΦs expressing the M1 phenotype reversed BC dormancy. Activation of M2a MΦs via the toll-like receptor 4 (TLR4) switched to M1 phenotype. The switch can occur by direct activation of M2a MΦs, or indirectly through activation of mesenchymal stem cells. M1 MΦ-derived exosomes activated NFкB to reverse quiescent BCCs to cycling cells. Using an in vivo model of BC dormancy, injected Mi MOs sensitized BCCs to carboplatin and increased host survival. In summary, we have shown how BM stromal MΦs, through exosomes, regulate the behavior of BCCs, by either inducing or reversing dormancy.

Highlights

  • Breast cancer (BC) cells (BCCs) may exist in cellular quiescence for decades[1,2]

  • bone marrow (BM) stromal M2 MΦs to M1 type In order to include all components of BM stroma to understand BC dormancy, nonhematopoietic cells and MΦs, stromal cultures are established with BM aspirates[10,30,31]

  • Since CD163 is expressed on endogenous BM MΦ, our model recapitulated occurrences in BM36

Read more

Summary

Introduction

Breast cancer (BC) cells (BCCs) may exist in cellular quiescence (dormancy) for decades[1,2]. Disseminated BCCs can enter the bone marrow (BM) long before detection[3,4]. This allows for the establishment of BC dormancy before clinical diagnosis, in addition to transition into cellular quiescence during the clinical course of the disease[5,6,7]. The anatomical location of the cancer cells with HSCs makes it difficult to target the dormant BCCs without untoward effects on the hematopoietic system[10]. An understanding of how BM stroma support BCC dormancy is important since the same stromal cells can cause BC resurgence[11,12,13]. BM stroma is Official journal of the Cell Death Differentiation Association

Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.